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Background: Proinflammatory cytokine tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and its
receptor Fn14 are the major regulators of skeletal muscle mass in many catabolic conditions. However, their role in
muscle metabolism remains largely unknown. In the present study, we investigated the role of TWEAK on exercise
capacity and skeletal muscle mitochondrial content and oxidative metabolism.
Methods: We employed wild-type and TWEAK-knockout (KO) mice and primary myotube cultures and performed
biochemical, bioenergetics, and morphometric assays to evaluate the effects of TWEAK on exercise tolerance and
muscle mitochondrial function and angiogenesis.
Results: TWEAK-KO mice showed improved exercise tolerance compared to wild-type mice. Electron microscopy
analysis showed that the abundance of subsarcolemmal and intermyofibrillar mitochondria is significantly increased
in skeletal muscle of TWEAK-KO mice compared to wild-type mice. Furthermore, age-related loss in skeletal muscle
oxidative capacity was rescued in TWEAK-KO mice. Expression of a key transcriptional regulator peroxisome
proliferator-activated receptor γ coactivator 1α (PGC-1α) and several other molecules involved in oxidative
metabolism were significantly higher in skeletal muscle of TWEAK-KO mice. Moreover, treatment of primary
myotubes with soluble TWEAK inhibited the expression of PGC-1α and mitochondrial genes and decreased
mitochondrial respiratory capacity. Deletion of TWEAK also improved angiogenesis and transcript levels of vascular
endothelial growth factor in skeletal muscle of mice.
Conclusions: These results demonstrate that TWEAK decreases mitochondrial content and oxidative
phosphorylation and inhibits angiogenesis in skeletal muscle. Neutralization of TWEAK is a potential approach for
improving exercise capacity and oxidative metabolism in skeletal muscle.
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Skeletal muscle is the largest tissue of the human body
which ensures basic functions such as locomotion, me-
tabolism, and respiration. Skeletal muscle exhibits a high
level of plasticity in response to physiological stressors.
For example, in response to exercise training, the pro-
portion of slow-type fibers and mitochondrial content
within fibers is noticeably increased [1]. The biogenesis* Correspondence: ashok.kumar@louisville.edu
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reproduction in any medium, provided the orof new mitochondria and clearance of defunct mitochon-
dria are essential to meet cellular energy demand especially
during endurance exercise and to protect from many
chronic conditions such as diabetes, heart failure, obesity,
and aging [2,3]. Peroxisome proliferator-activated receptor
(PPAR)-γ coactivator 1α (PGC-1α) is a key player in
regulating skeletal muscle fiber composition, mitochondrial
content, and oxidative metabolism, and maintenance of
glucose, lipid, and energy homeostasis in response to
physiological demands [4-6]. Transgenic mice overexpre-
ssing physiological levels of PGC-1α in skeletal muscle have
increased mitochondrial biogenesis and oxidative capacity,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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performance [7-10]. Forced expression of PGC-1α also
preserves skeletal muscle mass in various catabolic states
including denervation [11,12]. PGC-1α improves mito-
chondrial biogenesis by coactivating nuclear respiratory
factor (NRF)-1 [13], NRF-2 [14] and estrogen-related
receptor α [15-17] which, in turn, augments the expression
of hundreds of nuclear-coded mitochondrial genes [18].
Recent evidence also suggests a role for mitochondria in
preventing muscle protein degradation in catabolic condi-
tions [19,20]. Thus, preserving mitochondria content and
function is essential to countering muscle wasting and to
improvingmuscle homeostasis.
Inflammatory cytokines such as tumor necrosis factor-α
(TNF-α) and interleukin-6 (IL-6) are some of the import-
ant mediators of loss of skeletal muscle mass and function
in many catabolic conditions [21-24]. TNF-α has been
reported to augment muscle protein degradation both
in vitro and in vivo [25-27]. Moreover, TNF receptor I
knockout (KO) mice are protected from diet-induced
obesity due to increased thermogenesis [28]. Importantly,
TNF-α inhibits the expression of PGC-1α levels in
myotubes [29]. In animal models of cancer cachexia, mito-
chondrial content and biogenesis are reduced with in-
creased levels of IL-6 during the progression of the
condition whereas inhibition of IL-6 activity attenuates
tumor-induced loss of skeletal muscle [30,31]. It is also
notable that while moderate exercise attenuates inflamma-
tion [32-34], acute exercise more robustly increases the
levels of inflammatory cytokines in obese compared with
lean subjects suggesting that rigorous exercise can further
aggravate the condition of overweight individuals [35].
Despite these observations, cause-and-effect relationships
between different inflammatory mediators, exercise toler-
ance, and mitochondrial function in skeletal muscle have
not been clearly established using genetic mouse models.
TNF-like weak inducer of apoptosis (TWEAK) is a major
proinflammatory cytokine of the TNF super family [36]
that functions by binding to Fn14 receptors on target
cells [37-39]. TWEAK-Fn14 signaling mediates unique
and context-dependent pleiotropic effects [40]. TWEAK
has been recently identified to be a key mediator that
causes skeletal muscle loss that occurs in response to
denervation, immobilization, and starvation [21,41,42].
Moreover, TWEAK-transgenic mice overexpressing phy-
siological levels of TWEAK in skeletal muscle showed a
higher proportion of fast-type fibers (glycolytic) in soleus
and extensor digitorum longus (EDL) muscle [41] indi-
cating that elevated levels of TWEAK cause a slow-
to-fast type fiber switch. However, the role and mecha-
nisms by which TWEAK affects exercise capacity and
bioenergetic function have not been studied.
In the present study, we have used TWEAK-knockout
(KO) mice to investigate the role of TWEAK in exercisetolerance and skeletal muscle bioenergetic function.
Our results show that, compared with wild-type mice,
TWEAK-KO mice have increased exercise tolerance,
which is associated with higher levels of skeletal muscle
subsarcolemmal and intermyofibrillar mitochondria and
enhanced oxidative phosphorylation capacity. TWEAK
represses the expression of PGC-1α and several other
molecules involved in mitochondrial biogenesis and
oxidative metabolism in vivo and in cultured myotubes.
Furthermore, vascularization and expression of vascular
endothelial growth factor (VEGF) are increased in ske-
letal muscle of TWEAK-KO mice compared with wild-
type mice. These results support our hypothesis that
TWEAK causes exercise intolerance by suppressing
mitochondrial oxidative metabolism and angiogenesis.
Methods
Cell culture
Primary myoblasts were isolated from hind limb muscle
of mice and cultured following the same protocol as pre-
viously described [43]. Briefly, hind limb skeletal muscles
from mice were aseptically isolated, minced into a coarse
slurry, and enzymatically digested at 37°C for one hour
by adding 200 IU/ml collagenase I (cat # LS004196;
Worthington, Lakewood, NJ, USA) and 0.1% pronase
(EMD Chemicals, Billerica, MA, USA). The digested
slurry was filtered through a 70 μm filter and spun, and
isolated cells were resuspended and cultured initially in
F-10 medium (containing 20% fetal bovine serum (FBS)
and supplemented with 10 ng/ml basic fibroblast growth
factor) and then in F-10 plus (Dulbecco’s) Modified
Eagle’s Medium ((D)MEM) (1:1 ratio) based culture
medium supplemented with 15% FBS on culture dishes
coated with 10% matrigel (BD Biosciences, San Jose, CA,
USA). Differentiation in primary myoblast cultures was
induced by replacing the growth medium with differenti-
ation medium (2% horse serum in (D)MEM).
Animals
TWEAK-KO mice were provided by Dr. Avi Ashkenazi
(Genentech South, San Francisco, CA, USA) and have
been previously described [40]. All the mice were in the
C57BL/6 background, and their genotype was determined
by PCR from tail DNA. All animal procedures were
approved (protocol # 10129) by the Institutional Animal
Care and Use Committee and conformed to the American
Physiological Society’s Guiding Principles in the Care and
Use of Animals.
Treadmill running protocol
Mice were subjected to treadmill running following
the same previously described protocol [44]. In brief,
4.5-month-old wild-type and TWEAK-KO mice were
matched for body weight and randomly assigned to
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subjected to an acute bout of treadmill (Eco3/6 tread-
mill; Columbus Instruments, Columbus, OH, USA) run-
ning at 15 m/minute for 90 minutes. All mice in the
exercise group finished the 90-minute trial and were vis-
ibly exhausted. Mice were sacrificed within 30 minutes
after exercise to study mitochondrial function.
Exercise tolerance test
The exercise tolerance test on mice was performed fol-
lowing a method as previously described [45]. Briefly, all
animals were run on a treadmill (Columbus Instru-
ments) at 10 m/minutes for five minutes at 0% degree
incline for acclimation for three days. On the exercise
testing day, animals ran on the treadmill with a fixed
slope of 10%. Mice first ran at 10 m/minute for five mi-
nutes and the speed was increased by 2 m/minute every
two minutes until they were exhausted or a maximal
speed of 46 m/minute was achieved. The criterion of
exhaustion was defined as the inability of the animal to
run on the treadmill for 10 seconds despite mechanical
prodding. Running time and maximum speed achieved
was measured whereas running distance, work and power
were calculated.
Transmission electron microscopy
Soleus muscles from wild-type and TWEAK-KO mice
were fixed in 3% glutaraldehyde in 0.1 M cocodylate
buffer overnight followed by fixing in 1% cocodylate-
buffered osmium tetroxide. The tissue was dehydrated
through a series of graded alcohols, and embedded in
LX-112 plastic (Ladd Research Industries, Williston,
VT, USA). Longitudinal sections (80 nm) were cut
using an ultramicrotome (LKB, Rockville, MD, USA))
and stained with uranium acetate and lead citrate.
Samples were analyzed using a transmission electron
microscope (Philips CM 12; HZB, Berlin, Germany)
operating at 60 kV. The pictures were captured at
8,800x magnification using a 3.2 megapixel digital
camera (Sia-7C; Kodak, Rochester, NY, USA) at room
temperature. No imaging medium was used to
visualize the pictures, and images were stored as
JPEG files. Image levels were equally adjusted using
Photoshop CS2 software.
Succinate dehydrogenase (SDH) staining
SDH staining was performed as previously described
[46]. Briefly, transverse sections (8 μm) were cut from
the mid-belly of the TA muscles on a cryostat at −20°C
and stored at −80°C until SDH staining was performed.
The sections were dried at room temperature for 30 mi-
nutes before incubation in a solution made up of 0.2 M
phosphate buffer (pH 7.4), 0.1 M MgCl2, 0.2 M succinic
acid (Sigma Chemical Company, St. Louis, MO, USA)and 2.4 mM nitroblue tetrazolium (NBT, Sigma) at 37°C
in a humidity chamber for 45 minutes. The sections
were then washed in deionized water for three minutes,
dehydrated in 50% ethanol for two minutes, and mounted
for viewing with DPX mount medium (Electron Micros-
copy Sciences, Hatfield, PA, USA). Digital photographs
were taken from each section at 10X magnification under
a Nikon Eclipse TE 2000-U microscope (Nikon, Melville,
NY, USA) with a Nikon digital camera (Digital Sight DS-
Fi1), and fibers were quantified with imaging software
(Image J, NIH). At least 700 fibers were counted to deter-
mine SDH-positive fibers in each section in a blinded
fashion. The percentage of SDH stained fibers was then
determined based on a criteria using integrated optical
density.Measurement of mitochondrial bioenergetics
Mitochondrial oxidative capacity was measured in isolated
mitochondria and in cultured myotubes using a Seahorse
Bioscience XF24 extracellular flux analyzer (Billerica, MA,
USA). For measurements in isolated mitochondria, tissue
from the limb muscle (approximately 50 mg) was isolated
within 30 minutes of exercise and homogenized in 1 ml of
isolation buffer (220 mM mannitol, 70 mM sucrose, 5 mM
3-(N-morpholino)propanesulfonic acid (MOPS), 1 mM
ethylene glycol tetraacetic acid (EGTA), 0.3% fatty acid-free
BSA, pH 7.2) using a Potter Elvehjem tube and a Teflon
pestle. The homogenate was centrifuged at 500×g for five
minutes at 4°C. The supernatant containing mitochondria
was centrifuged at 10,000 × g for five minutes. After two
wash-centrifugation steps in BSA-free isolation buffer,
the mitochondria were suspended in respiration buffer
(120 mM KCl, 25 mM sucrose, 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 1 mM MgCl2, 5
mM KH2PO4, pH to 7.2). Protein in the mitochondrial sus-
pension was estimated using the Lowry DC assay (Biorad,
Hercules, CA, USA) and 5 to 12.5 μg of mitochondrial pro-
tein was sedimented in XF culture plates as described previ-
ously [47]. Complex I-mediated, state 3 respiratory activity
was determined bymeasuring the oxygen consumption rate
(OCR) after injection of pyruvate (5 mM), malate (2.5 mM)
and ADP (1mM). TheOCR ofmitochondria after exposure
to oligomycin (1 μg/ml) was used to estimate state 4 activ-
ity; exposure to carbonyl cyanide p-trifluoromethoxyphe
nylhydrazone (FCCP, 2 μM) was used to examine the
uncoupled rate of respiration. Finally, succinate (10 mM)
and rotenone (1 μM)were injected to assess maximal Com-
plex II-mediated respiratory capacity. Data are expressed as
pmol O2/min/μg protein. For measurements in cultured
cells, differentiated myoblasts were exposed to soluble
TWEAK (R&D Systems, Minneapolis, MN, USA) for 72
hours followed by the mitochondrial function assay
outlined previously [48-51].
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RNA isolation and quantitative real time-PCR (qRT-PCR)
were performed as previously described [41]. Briefly, total
RNA was isolated from homogenized mouse tissues using
the TRIzol reagent (Invitrogen, Grand Island, NY, USA)
and an RNeasy Mini kit (QIAGEN, Valencia, CA, USA)
according to the manufacturers’ protocols. First strand
cDNA for PCR analyses were made using a reverse
transcription system with 1 μg of purified RNA using oligo
(dT) primer (Applied Biosystems, Grand Island, NY, USA)
and the Omniscript reverse transcription kit (QIAGEN).
The quantification of mRNA expression was performed
using the SYBR green dye method on a sequence detec-
tion system (Applied Biosystems, model 7300). Primers
were designed using Vector NTI software (Invitrogen).
Primer sequences are available on request. The thermal
conditions consisted of an initial denaturation at 95°C for
10 minutes, followed by 40 cycles of denaturation at 95°C
for 15 seconds, annealing and extension at 60°C for one
minute, and, for a final step, a melting curve of 95°C for
15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds.
All reactions were performed in duplicate to reduce vari-
ation. Data normalization was accomplished using the
endogenous control (β-actin), and the normalized values
were subjected to a 2-ΔΔCt formula to calculate the fold
change between control and experimental groups.Immunostaining for CD31
After cutting 8 μm thickness frozen sections of TA
muscles, the sections were fixed by cold acetone for 10
minutes and dried in air for 30 minutes. The tissues
were rinsed with phosphate buffered saline (PBS) twice,
blocked in 2% BSA solution for one hour at room
temperature followed by incubation with primary anti-
bodies in 2% BSA solution (laminin, anti-rabbit 1:300,
Sigma and CD31, anti-mouse 1:30, BD Biosciences, San
Jose, CA, USA) at 4°C in a humidity chamber overnight.
The next day, the sections were rinsed with PBS for five
minutes three times and incubated with secondary anti-
body (Alexa Fluor-conjugated 488 anti-rabbit, 1:2500
and 546 anti-mouse, 1:2500, Invitrogen) in 2% BSA solu-
tion for one hour at room temperature. After washing
twice with PBS and once with deionized water, the
sections were mounted with DPX mounting medium.
Digital photographs were taken from each section under
a Nikon Eclipse TE 2000-U microscope (Nikon) with a
Nikon digital camera (Digital Sight DS-Fi1). Number of
CD31-postive vessels per myofiber was quantified using
NIS Elements BR 3.00 software (Nikon).Statistical analysis
The results are presented as means ± standard deviation
(SD). Student’s t-test was used to compare the differencebetween control and treatment groups. A value P <0.05
was considered statistically significant.
Results
Improvement in exercise tolerance in TWEAK-KO mice
We first studied the role of TWEAK in exercise tolerance
in mice. Male 4.5-month old wild-type and TWEAK-KO
mice were acclimated for three days for treadmill running
prior to the exercise tolerance test. After acclimation, the
mice were run on a 10% slope until the mice were unable
to run on the treadmill for 10 seconds despite mechanical
prodding. TWEAK-KO mice ran longer compared to
wild-type mice (1,483 seconds for TWEAK-KOs versus
1,170 seconds for the controls, Figure 1A). Since TWEAK-
KO mice could keep running on higher speed (30.6 m/
minute for TWEAK-KOs versus 25.5 m/minute for the
controls, Figure 1B), the difference in running distance
became greater than 47% (463 meter for TWEAK-KOs
versus 314 meter for the controls, Figure 1C). Work and
power generated by TWEAK-KO mice were also higher
compared to wild-type mice. TWEAK-KO mice generated
22.2 J of work while control mice generated 15.2 J of work
(a difference of 46%) during the exercise test (Figure 1D).
In turn, TWEAK-KO mice exerted 14% more power than
the controls (14.9 mW for TWEAK-KO versus 13.0 mW
for the wild-type, Figure 1E) on the treadmill. These data
established that TWEAK-KO mice have significantly im-
proved exercise tolerance.
Ablation of TWEAK improves mitochondrial content in
skeletal muscle of mice
We have previously shown that deletion of TWEAK in-
creases the proportion of type I fibers in soleus and EDL
muscles of mice [41]. In this study, we investigated
whether TWEAK affects mitochondrial content in skel-
etal muscle of mice. The soleus muscle of 4.5-month old
TWEAK-KO and wild-type mice were isolated and used
to measure mitochondrial content by performing trans-
mission electron microscopy. As shown in Figure 2A,
the abundance and size of mitochondria was found to be
increased in TWEAK-KO compared to wild-type mice.
Quantitative analysis of mitochondria in electron micro-
graphs showed that the levels of subsarcolemmal and
intermyofibrillar mitochondria were increased by 42%
and 32%, respectively, in TWEAK-KO mice compared to
wild-type mice (Figure 2B and Figure 2C). Because
gastrocnemius (GA) muscle contains a mixture of slow and
fast twitch fibers and greatly influences running capacity on
the treadmill, we measured mRNA levels of fiber type-
specific myosin heavy chain (MyHC) isoforms in GA
muscle of wild-type and TWEAK-KO mice. As shown in
Figure 2D, mRNA levels of MyHC I and MyHC IIA were
increased by 2- and 2.7-fold, respectively in TWEAK-KO
mice compared to wild-type mice. These results further
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Figure 1 Treadmill exercise tolerance test. After acclimatization, mice were run on a treadmill with a 10% slope and increasing speed to
exhaustion. Maximum speed and running time were monitored, and distance, work, and power were calculated based on the individual
performance. (A) Running time; (B) Speed; (C) Distance; (D) Work; and (E) Power. Data are represented as mean ± SD. N = 6 in each group.
*P <0.05; values vary significantly between wild-type and TWEAK-KO mice. KO, knockout.
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slow-type fiber phenotype in skeletal muscle of mice.
SDH, also known as complex II in the mitochondrial
respiratory chain, is a marker of oxidative capacity of skel-
etal muscle at the fiber level. Therefore, we performed
SDH staining on TA muscle of 4.5-month- and 12-month-
old wild-type mice and TWEAK-KO mice and quantified
the percentage of SDH-positive fibers. Compared to wild-
type mice, fibers in TWEAK-KO mice stained more darkly
for SDH (Figure 3A). Furthermore, there was a significant
increase in the number of SDH-positive fibers in TWEAK-
KO mice compared to wild-type mice at the age of 4.5
months (Figure 3B). Likewise, 12-month-old TWEAK-KO
had more SDH-positive fibers compared to age-matched
wild-type mice (Figure 3A and Figure 3C). Taken together,
these results suggest that ablation of TWEAK in mice is
sufficient to improve mitochondrial content and oxidative
capacity of skeletal muscle.
TWEAK-KO mice demonstrate increased expression of
PGC-1α and metabolic genes in skeletal muscle
To understand the mechanisms by which TWEAK affects
exercise capacity and mitochondrial content in skeletalmuscle, we investigated whether TWEAK modulates the
expression of PGC-1α, a critical regulator of the mito-
chondrial biogenetic program in skeletal muscle [9,10].
Interestingly, the mRNA levels of PGC-1αwere found to be
significantly higher in 4.5-month-old TWEAK-KO mice
compared to age-matched wild-type mice (Figure 4).
Similarly, mRNA levels of PPARδ were significantly higher
in skeletal muscle of TWEAK-KOmice compared to corre-
sponding wild-type mice (Figure 4). In contrast, mRNA
levels of glycolytic enzymes such as hexokinase-2 (HK II)
and phosphoglycerate mutase 2 (PGAM2) were reduced in
skeletal muscle of TWEAK-KO mice compared to wild-
type mice. No significant change was observed in the
expression of pyruvate dehydrogenase kinase-4 (PDK4).
Furthermore, mRNA levels of mitochondrial carnitine
palmitoyltransferase I (mCPT1), which is required for the
transport of long-chain fatty acyl-CoAs from the cyto-
plasm into the mitochondrion, were significantly ele-
vated in TWEAK-KO mice compared to wild-type mice
(Figure 4). These results suggest that a deficiency of
TWEAK reduces expression of glycolytic genes and
augments the expression of genes involved in oxidative
metabolism in skeletal muscle.
Figure 2 Transmission electron microscopy (TEM) analysis for mitochondria morphology and content and expression of muscle fiber
type-specific genes in TWEAK-KO mice. Soleus muscle of six-month-old wild-type and TWEAK-KO mice were isolated and longitudinal sections
were processed for TEM analysis. (A) Representative images of longitudinal soleus muscle are shown. The abundance and the size of mitochondria
were increased in TWEAK-KO mice compared to wild-type mice. Arrows point to mitochondria in muscle sections. Circles are used to show
representative enlarged mitochondria. Stars (‘*’) point to subsarcolemmal space in longitudinal sections. Scale bar: 1 μm. (B) Quantification of the
number of subsarcolemmal mitochondria in soleus muscle of wild-type and TWEAK-KO mice. (C) Quantification of the number of intermyofibrillar
mitochondria in soleus muscle sections of wild-type and TWEAK-KO mice. (D) Relative mRNA levels of MyHC type I, IIA and IIB in gastrocnemius
muscle of 4.5-month-old wild-type and TWEAK-KO mice. Data are represented as mean ± SD. N = 3 in each group. *P <0.05; values vary significantly
from wild-type mice. KO, knockout; TWEAK, TNF-like weak inducer of apoptosis.
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skeletal muscle mitochondria
We next sought to determine whether TWEAK regulates
mitochondrial function in skeletal muscle. After an acute
bout of treadmill running for 90 minutes, mitochondria
were isolated from hind limb muscles of wild type and
TWEAK-KO mice and mitochondrial function was exam-
ined by extracellular flux (XF) analysis. The sequential
addition of respiratory substrates and inhibitors of oxi-
dative phosphorylation were used to determine changes in
electron transport chain activity: state 3 respiration wasinduced by addition of pyruvate, malate and ADP; state 4
respiration was induced by addition of oligomycin; FCCP
was added to determine maximal complex I-mediated
respiratory activity; and, lastly, succinate and rotenone
were added to determine maximal complex II-mediated
respiratory activity. As shown in Figure 5A and 5B, mito-
chondria from TWEAK-KO mice showed significantly in-
creased state 3 respiratory activities compared with wild
type mice. Mitochondrial coupling (as determined by
calculating respiratory control ratios) and other indices of
mitochondrial function were not significantly different
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Figure 3 Succinate dehydrogenase (SDH) staining analysis for oxidative capacity in TA muscle of TWEAK-KO mice. Frozen transverse TA
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absence of TWEAK augments mitochondrial oxidative
capacity in skeletal muscle in exercised mice.TWEAK represses the expression of PGC-1α and genes
regulating oxidative metabolism in cultured primary
myotubes
We next studied whether TWEAK affects the expression
of PGC-1α and other genes in cultured primary myotubes.
Primary myoblasts prepared from wild-type mice were dif-
ferentiated into myotubes by incubation in differentiation
medium for 96 hours followed by treatment with TWEAK
for 72 hours. As shown in Figure 6, addition of soluble
TWEAK dramatically reduced the expression of PGC-1α
in myotubes. Treatment with TWEAK also significantly
reduced the mRNA levels of several mitochondrial genes
encoding proteins related to oxidative metabolism, such
as ATP synthase subunit beta (ATP5b), cytochrome c oxi-
dase subunit I (Cox I), Cox subunit IV (COX IV), COX -
7b, cytochrome c (Cyt c), medium-chain acyl-coenzyme A
dehydrogenase (MCAD), PPARδ, and mCPT1 (Figure 6).
These results further suggest that TWEAK inhibits the
mitochondrial biogenetic program in skeletal muscle.TWEAK decreases maximal respiratory capacity and
increases glycolysis in cultured primary myotubes
Our studies in isolated mitochondria derived from ske-
letal muscle after exercise suggest that the absence of
TWEAK increases mitochondrial oxidative capacity. Toassess the effects of TWEAK on mitochondrial function
directly, we exposed differentiated myotubes to TWEAK
and then assessed mitochondrial function as described
previously [48-51]. As shown in Figure 7A and 7B, ex-
posure of myotubes to TWEAK for 72 hours did not
affect the basal mitochondrial OCR, nor did it affect
ATP-linked OCR or proton leak. However, the FCCP-
stimulated OCR, indicative of maximal respiratory cap-
acity, was remarkably diminished by TWEAK treatment.
In addition, a modest, yet significant, increase in the
non-mitochondrial OCR occurred in myotubes exposed
to100 ng/ml TWEAK, which may be due to increased
production of reactive oxygen species. The diminishment
in mitochondrial respiratory capacity caused by TWEAK
was associated with an increase in the extracellular acid-
ification rate (ECAR), a surrogate measure of glycolysis
(Figure 7C). Collectively, these results suggest that
TWEAK directly modulates the bioenergetic capacity of
skeletal muscle.
Ablation of TWEAK improves angiogenesis in skeletal
muscle of mice
There is a causal relationship between PGC-1α and
angiogenesis. Skeletal muscle-specific overexpression of
PGC-1α in mice results in increased angiogenesis, which
may contribute to enhanced exercise performance [52].
Since TWEAK suppresses PGC-α in skeletal muscle, we
next sought to determine whether TWEAK also regu-
lates angiogenesis in skeletal muscle of mice. TA muscle
of 4.5-month-old wild-type and TWEAK-KO mice
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http://www.skeletalmusclejournal.com/content/3/1/18was isolated and immunostained with antibodies against
CD31 (also known as platelet endothelial cell adhesion
molecule-1), an endothelial-specific marker for capilla-
ries. Laminin staining was used to mark the periphery
of fibers. As shown in Figure 8A, the number of CD31-
positive capillaries was considerably increased in TWEAK-
KO mice compared with wild-type mice. The capillary-
to-fiber ratio was increased by 29% in TWEAK-KO mice
(Figure 8B). Since VEGF positively regulates angiogenesis,
we also measured mRNA levels of VEGF in TA muscle of
wild-type and TWEAK-KO mice. As shown in Figure 8C,
mRNA levels of VEGF were significantly higher in TA
muscle of TWEAK-KO mice compared to wild-type mice.
Furthermore, treatment with TWEAK also reduced the
mRNA levels of VEGF in primary myotubes (Figure 8D).
These results suggest that ablation of TWEAK stimulates
angiogenesis in skeletal muscle of mice potentially through
increasing the expression of VEGF.
Discussion
Exercise capacity in mammals is determined by multiple
factors including skeletal muscle oxidative metabolism
and vascularization. Our previous microarray study sug-
gested that TWEAK can modulate the expression of sev-
eral genes whose products are involved in mitochondrial
dysfunction and fatty acid metabolism [53]. Our present
study demonstrates that compared to wild-type mice,
TWEAK-KO mice run longer and with higher speed
during an exercise tolerance test (Figure 1). TWEAK-
KO mice show augmented levels of subsarcolemmal andintermyofibrillar mitochondria, increased SDH-positive
myofibers, and elevated expression of metabolic genes
such as PGC-1α, PPARδ, and mCPT-1 compared to wild-
type mice (Figures 2, 3, and 4). Oxidative phosphorylation
is also increased in exercised TWEAK-KO mice compared
with wild-type mice (Figure 5), and treatment of myotubes
with TWEAK directly decreases mitochondrial biogenetic
capacity and maximal respiratory activity (Figures 6 and
7). Moreover, vascularization and expression of VEGF in
skeletal muscle are enhanced in TWEAK-KO mice com-
pared to their controls (Figure 8). These data suggest that
TWEAK directly regulates the mitochondrial biogenetic
program and that loss of TWEAK improves mitochondrial
respiratory capacity and increases vascularization of ske-
letal muscle tissue, which collectively lead to improved
exercise performance.
One of the potential mechanisms by which TWEAK
might be attenuating exercise capacity is through
diminishing the levels of PGC-1α in skeletal muscle.
PGC-1α augments mitochondrial biogenesis, oxidative
metabolism, and promotes fast-to-slow type fiber tran-
sition [9,13,17,54-56]. Overexpression of PGC-1α in rat
primary culture cells leads to increased abundance of
slow oxidative-associated MyHC isoform [57]. Skeletal
muscle-specific PGC-1α KO mice demonstrate reduced
endurance capacity with a shift from oxidative fiber type
to glycolytic fibers and increased levels of TNF-α in
skeletal muscle [45,58]. By contrast, muscle-specific
overexpression of PGC-1α enhances exercise perfor-
mance with increased fatty acid oxidation and decreased
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http://www.skeletalmusclejournal.com/content/3/1/18glycogen usage during exercise [8,52]. These findings
suggest that PGC-1α is not only essential but sufficient
to determining skeletal muscle fiber composition. Our
experiments demonstrate that mRNA levels of PGC-1α
are increased in skeletal muscle of TWEAK-KO mice
with a concomitant increase in mitochondrial content
and expression of genes whose products are involved in
oxidative capacity (Figures 2 and 4). Furthermore, treat-
ment of primary myotubes with TWEAK drastically re-
duced levels of PGC-1α and other mitochondrial genes
(Figure 6) further suggesting that TWEAK represses the
expression of PGC-1α leading to reduced mitochondrial
content. These findings are consistent with functional
analyses of mitochondrial function: ablation of TWEAK
resulted in increased oxidative phosphorylation capacity
in isolated mitochondria (Figure 5) and treatment of
myotubes with TWEAK decreased maximal respiratory
capacity (Figure 7). Although not tested in this study, it
is possible that TWEAK also reduces the levels of PGC-
1α in other organs which ultimately results in reduced
exercise capacity. Indeed, Shi et al. recently reported
that TWEAK represses the expression of PGC-1α andother molecules involved in mitochondrial oxidative
phosphorylation in cardiomyocytes and forced expres-
sion of PGC-1α attenuates TWEAK-induced cardiac
dysfunction in mice [59].
The PPARs are ligand-modulated transcription factors
in which three subtypes have been identified: α, β/δ, and
γ [60]. Previous studies have shown that their endogen-
ous ligands are composed of fatty acids and lipid me-
tabolites and, therefore, certain PPARs mediate the
expression of genes whose products are involved in the
regulation of fatty acid metabolism in response to
changes in systemic fuel availability [60-62]. In skeletal
muscle, levels of PPARδ are relatively higher compared
to PPARα or PPARγ [63]. Treatment with synthetic
PPARδ agonist or overexpression of PPARδ by retroviral
infection induces the levels of molecules which are in-
volved in lipid metabolism and fatty acid oxidation,
whereas overexpression of a dominant-negative PPARδ
mutant exerts opposite effects in C2C12 myotubes [64].
Furthermore, it has been shown that muscle-specific
overexpression of PPARδ in mice increases exercise
tolerance with a switch to increased number of type I
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fatty acid metabolism. In contrast, PPARδ-null mice
show decreased exercise performance compared to wild-
type mice [65,66]. Although muscle relies mainly on fat
and carbohydrate as energy resources, enhanced fatty
acid utilization during exercise with glycogen sparing re-
sults in improved exercise endurance capacity [67-69].
Haramizu et al. demonstrated that the expression levels
of gene products related to lipid metabolism in the
muscle is correlated with the levels of fatty acid β-
oxidation activity as well as exercise strength [70]. Our
results demonstrate that transcript levels of PPARδ and
mCPT1 are significantly increased while the expression
of molecules that are associated with glycolysis such as
HK II and PGAM2 is suppressed in skeletal muscle of
TWEAK-KO mice compared to wild-type mice (Figure 6).
These results suggest that enhanced fatty acid oxidationmight be responsible for improvement in exercise capacity
in TWEAK-KO mice. Data from cell culture experiments
further support this possibility, as treatment of myotubes
with TWEAK resulted in diminished maximal respiratory
capacity and increased glycolytic flux (Figure 7).
Although the mechanisms by which TWEAK reduces
levels of PGC-1α in skeletal muscle remain unknown, a
recent study has shown that TWEAK increases membrane
translocation of adaptor protein TNF receptor associated
factor 2 (TRAF2), in an Fn14 dependent manner, in car-
diomyocytes [59]. Furthermore, TWEAK treatment in-
creases the activation of canonical nuclear factor-kappaB
(NF-κB) signaling in both skeletal muscle [41] and cardiac
myocytes [59]. Knockdown of TRAF2 using small hair-
pin RNA (shRNA) or selective blockade of IκB kinase-β
(IKKβ, an upstream activator of canonical NF-κB signal-
ing) prevented the TWEAK-mediated suppression of
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http://www.skeletalmusclejournal.com/content/3/1/18PGC-1α in cardiomyocytes suggesting that TWEAK re-
pression of PGC-1α requires Fn14-TRAF2-IKKβ-NF-κB
signaling cascade [59]. Previously, the effects of TNF-α
on the mRNA expression of PPARδ and its target genes
have been investigated. Treatment with TNF-α reduces
PPARδ-target genes, such as mCPT1 and PGC-1α,
whereas addition of PPARδ agonist rescues this reduc-
tion in adipocytes [71,72]. Moreover, TNF-α impairs
mitochondrial biogenesis and function in skeletal
muscle [73]. While TWEAK can induce the expression
of molecules associated with the autophagy-lysosomal
system indicating it causes mitochondria dysfunction
[74], muscle-specific ablation of TRAF6, which is in-
volved in TWEAK signaling, suppresses the activation
of autophagy in response to denervation and cancer
cachexia [75]. These results suggest that TWEAK is in-
volved in reducing PPARδ and PGC-1α levels and their
target genes leading to mitochondrial dysfunction and
content. Since no change of PPARδ expression was
observed in skeletal muscle of PGC-1α KO mice or the
muscle-specific PGC-1α overexpressing transgenic mice
[66], PGC-1α is not an upstream regulator for PPARδ.
Indeed, PGC-1α has a synergistic effect with PPARδ
agonist to induce the expression of oxidative metabolic
genes such as mCPT1 and PDK4 [76]. Furthermore, it
has been shown that PGC-1α directly coactivates the
mCPT1 and PDK4 promoter via PPARδ in a ligand-
dependent manner [76,77]. Therefore, it is likely that
PGC-1α is a coactivator of PPARδ in terms of up-
regulating these metabolic genes.
Another interesting observation of the present study is
that depletion of TWEAK improves angiogenesis in ske-
letal muscle of mice (Figure 8). Previous studies have
shown that transgenic mice overexpressing PGC-1α show
increased vascularization in skeletal muscle [56]. PGC-1α
is also a positive regulator for the expression of VEGF1
which is known to promote angiogenesis [56]. Moreover,
human endothelial cells treated with the PPARδ agonist
GW501516 demonstrated increased production of VEGF
and expression of VEGF receptor [78,79]. Therefore, in-
creased angiogenesis in skeletal muscle of TWEAK-KO
mice appears to be a result of increased amounts of
PGC-1α and PPAR δ (Figure 4). The enhancement of
vascularization in TWEAK-KO mice might further
augment the capacity of skeletal muscle mitochondria to
respire by increasing blood flow and delivery of O2 and
nutrients, especially during exercise.
Conclusion
In summary, our study provides initial evidence that in-
hibition of TWEAK increases mitochondrial biogenesis,
oxidative metabolism and angiogenesis in skeletal muscle
which potentially contribute to improved exercise capacity.
These findings also have high clinical significance asinhibition of TWEAK activity using neutralizing antibodies
or pharmacological compounds could improve muscle
function and exercise capacity in patients with meta-
bolic disorders.
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